MedTrace Logo

Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity

NCT07029126 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-06-19

No results posted yet for this study

Summary

To evaluate the reduction of emotional burden (measured by Relative Stress Scale-RSS) of caregivers of migraine patients with Depressive Symptoms after 6 months after the first injection of fremanezumab.

Conditions

Interventions

DRUG

Fremanezumab

subcutaneous injection 225 mg monthly or 675 mg quarterly

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    collaborator INDUSTRY

  • Fondazione Policlinico Universitario Campus Bio-Medico

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-03
Primary Completion
2025-10-30
Completion
2026-03-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07029126 on ClinicalTrials.gov